Biogroup €1bn 5.25yr TLB A&E: FV ~E+495 vs IPT E+513–525
Biogroup (CAB) launched a min €1bn 5.25yr TLB A&E at E+450, 0% floor, OID 97.00–97.50, alongside a parallel new € SSN and €400m cash sweep. Talk implies DM E+513–525 on a 4yr WAL basis. Triangulating off Synlab/Ephios secondary, fair value lands ~E+495, leaving 18–30bp of NIC on offer. Base case: upsize toward €1.25bn, OID firms to 97.50, spread holds at E+450.
Setup
Biogroup is rolling its €1.75bn 2028 TLB and 3.375% 2028 SSN stack into new paper maturing Aug-31, supported by parallel SSN issuance and €400m balance sheet cash. Ratings TBA (historically B2/B-/B+). The relevant primary anchor remains the Dec-23 Synlab/Ephios package — same sector, similar sponsor archetype, comparable rating cluster, identical tariff-cycle exposure.
Synlab read-across
Synlab TLB Level Coupon margin E+475 Secondary price 99.50 Residual tenor 3.7yr DM (mid) E+488
The Synlab 7.875% 2031 SSN trades 6.39% bid YTM, ~G+350 to swaps — the sector has compressed roughly 190bp YTM since launch as the 2024–26 French tariff freeze improved visibility.
Biogroup DM at price talk
97.00 OID 97.50 OID Coupon margin E+450 E+450 OID drag (4yr WAL) +75bp +62bp Implied DM E+525 E+512
Fair value build
Component bp Synlab TLB secondary DM E+488 Credit gap (deeper French concentration, weaker margin) +5 New issue / A&E concession +0 to +5 Fair value range E+490–500
Mid-point FV: ~E+495 DM.
NIC vs price talk
Scenario Talk DM FV NIC OID 97.00 E+525 E+495 +30bp OID 97.50 E+512 E+495 +17bp
Landing call
Bias toward OID firming at allocation. Spread anchored at E+450 by ratings TBA risk and parallel SSN execution dynamics. Expected size: €1.25bn (upsized from €1bn floor). Expected landing: OID 97.50 firm, implied DM ~E+513 (4yr WAL), ~18bp NIC vs Synlab secondary — fair, not generous. Watch ratings drop, SSN tranche bookbuild, and existing-TLB roll mechanics for finalization signal.
Disclaimer: This post is for informational purposes only and does not constitute investment advice, an offer or solicitation to buy or sell any security, or a recommendation of any kind. Levels and views reflect the author's analysis at time of writing and are subject to change without notice. Readers should conduct their own due diligence and consult appropriate professional advisors before making any investment decision.
